A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
14hon MSN
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results